{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:19:45Z","timestamp":1792815585797,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100005006","name":"Asan Institute for Life Sciences, Asan Medical Center","doi-asserted-by":"publisher","award":["2021IT0008"],"award-info":[{"award-number":["2021IT0008"]}],"id":[{"id":"10.13039\/501100005006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1245\/s10434-026-19762-3","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T15:41:52Z","timestamp":1778168512000},"page":"7503-7511","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Modified FOLFIRINOX with or Without Stereotactic Body Radiation in Locally Advanced Unresectable Pancreatic Cancer (SABER): A Randomized Open-Label Phase 2 Trial"],"prefix":"10.1245","volume":"33","clinical-trial-number":[{"clinical-trial-number":"nct0498693","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Changhoon","family":"Yoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyehyun","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inkeun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaekyung","family":"Cheon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baek-Yeol","family":"Ryoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyu-pyo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Wook","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki-Byung","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woohyung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song Cheol","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Jun","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongwook","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Sung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Soo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-hong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"19762_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA: A Cancer J Clin"},{"key":"19762_CR2","first-page":"7","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. Ca Cancer J Clin. 2020;70:7\u201330.","journal-title":"Ca Cancer J Clin"},{"key":"19762_CR3","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.03.056","author":"LD Wood","year":"2022","unstructured":"Wood LD, Canto MI, Jaffee EM, Simeone DM. Pancreatic cancer: pathogenesis, screening, diagnosis and treatment. Gastroenterology. 2022. https:\/\/doi.org\/10.1053\/j.gastro.2022.03.056.","journal-title":"Gastroenterology"},{"key":"19762_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41571-023-00746-1","volume":"20","author":"C Springfeld","year":"2023","unstructured":"Springfeld C, Ferrone CR, Katz MHG, et al. Neoadjuvant therapy for pancreatic cancer. Nat Rev Clin Oncol. 2023;20:1\u201320.","journal-title":"Nat Rev Clin Oncol"},{"key":"19762_CR5","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ejca.2022.12.014","volume":"181","author":"M Ozaka","year":"2023","unstructured":"Ozaka M, Nakachi K, Kobayashi S, et al. A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407). Eur J Cancer. 2023;181:135\u201344.","journal-title":"Eur J Cancer"},{"key":"19762_CR6","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S1470-2045(16)00172-8","volume":"17","author":"M Suker","year":"2016","unstructured":"Suker M, Beumer BR, Sadot E, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016;17:801\u201310.","journal-title":"Lancet Oncol"},{"key":"19762_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S2468-1253(19)30327-9","volume":"5","author":"PA Philip","year":"2020","unstructured":"Philip PA, Lacy J, Portales F, et al. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. Lancet Gastro Hepatol. 2020;5:1\u201310.","journal-title":"Lancet Gastro Hepatol"},{"key":"19762_CR8","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Eng J Med. 2011;364:1817\u201325.","journal-title":"N Eng J Med"},{"key":"19762_CR9","first-page":"232","volume":"13","author":"SY Moorcraft","year":"2014","unstructured":"Moorcraft SY, Khan K, Peckitt C, et al. FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience. Clin Colorectal Cancer. 2014;13:232\u20138.","journal-title":"Clin Colorectal Cancer"},{"key":"19762_CR10","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1634\/theoncologist.2012-0435","volume":"18","author":"JE Faris","year":"2013","unstructured":"Faris JE, Blaszkowsky LS, McDermott S, et al. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Oncologist. 2013;18:543\u20138.","journal-title":"Oncologist"},{"key":"19762_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41416-020-0867-x","volume":"123","author":"C Yoo","year":"2020","unstructured":"Yoo C, Lee SS, Song KB, et al. Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biomarker analysis. Brit J Cancer. 2020;123:1\u20137.","journal-title":"Brit J Cancer"},{"key":"19762_CR12","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","volume":"379","author":"T Conroy","year":"2018","unstructured":"Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379:2395\u2013406.","journal-title":"N Engl J Med"},{"key":"19762_CR13","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1002\/jso.25233","volume":"118","author":"M Suker","year":"2018","unstructured":"Suker M, Nuyttens JJ, Koerkamp BG, Eskens FALM, van Eijck CHJ. FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: a cohort study. J Surg Oncol. 2018;118:1021\u20136.","journal-title":"J Surg Oncol"},{"key":"19762_CR14","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41575-023-00856-2","volume":"21","author":"TF Stoop","year":"2023","unstructured":"Stoop TF, Theijse RT, Seelen LWF, et al. Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2023;21:101\u201324.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"19762_CR15","doi-asserted-by":"publisher","first-page":"4105","DOI":"10.1200\/JCO.2011.34.8904","volume":"29","author":"PJ Loehrer Sr","year":"2011","unstructured":"Loehrer Sr PJ, Feng Y, Cardenes H, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2011;29:4105\u201312.","journal-title":"J Clin Oncol"},{"key":"19762_CR16","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1093\/annonc\/mdn281","volume":"19","author":"B Chauffert","year":"2008","unstructured":"Chauffert B, Mornex F, Bonnetain F, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000\u201301 FFCD\/SFRO study. Ann Oncol. 2008;19:1592\u20139.","journal-title":"Ann Oncol"},{"key":"19762_CR17","doi-asserted-by":"publisher","first-page":"e0214970","DOI":"10.1371\/journal.pone.0214970","volume":"14","author":"J Jung","year":"2019","unstructured":"Jung J, Yoon SM, Park J-H, et al. Stereotactic body radiation therapy for locally advanced pancreatic cancer. PLoS ONE. 2019;14:e0214970-e215012.","journal-title":"PLoS ONE"},{"key":"19762_CR18","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.3390\/cancers14051166","volume":"14","author":"YS Shin","year":"2022","unstructured":"Shin YS, Park HH, Park J, et al. Stereotactic body radiation therapy versus concurrent chemoradiotherapy for locally advanced pancreatic cancer: a propensity score-matched analysis. Cancers. 2022;14:1166.","journal-title":"Cancers"},{"key":"19762_CR19","doi-asserted-by":"publisher","first-page":"175883592110458","DOI":"10.1177\/17588359211045860","volume":"13","author":"C Bouchart","year":"2021","unstructured":"Bouchart C, Engelholm J-L, Closset J, et al. Isotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatment of localized pancreatic ductal adenocarcinoma. Ther Adv Med Oncol. 2021;13:17588359211045860.","journal-title":"Ther Adv Med Oncol"},{"key":"19762_CR20","doi-asserted-by":"publisher","first-page":"175883592095329","DOI":"10.1177\/1758835920953294","volume":"12","author":"C Yoo","year":"2020","unstructured":"Yoo C, Hwang I, Song TJ, et al. FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma. Ther Adv Med Oncol. 2020;12:1758835920953294.","journal-title":"Ther Adv Med Oncol"},{"key":"19762_CR21","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1001\/jama.2016.4324","volume":"315","author":"P Hammel","year":"2016","unstructured":"Hammel P, Huguet F, van Laethem J-L, et al. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib. JAMA. 2016;315:1844\u2013910.","journal-title":"JAMA"},{"issue":"supple","key":"19762_CR22","doi-asserted-by":"publisher","first-page":"4008","DOI":"10.1200\/JCO.2022.40.16_suppl.4008","volume":"40","author":"R Fietkau","year":"2022","unstructured":"Fietkau R, Ghadimi M, Grutzmann R, et al. Randomized phase III trial of induction chemotherapy followed by chemoradiotherapyor chemotherapy alone for nonresectable locally advanced pancreatic cancer: first results of the CONKO-007 trial. J Clin Oncol. 2022;40(supple):4008.","journal-title":"J Clin Oncol"},{"key":"19762_CR23","doi-asserted-by":"publisher","first-page":"783","DOI":"10.6004\/jnccn.2022.7008","volume":"20","author":"QP Janssen","year":"2022","unstructured":"Janssen QP, van Dam JL, Prakash LR, et al. Neoadjuvant radiotherapy after (m)FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: a TAPS Consortium Study. J Natl Compr Canc Ne. 2022;20:783-791.e1.","journal-title":"J Natl Compr Canc Ne"},{"key":"19762_CR24","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1001\/jamaoncol.2022.2319","volume":"8","author":"MHG Katz","year":"2022","unstructured":"Katz MHG, Shi Q, Meyers J, et al. Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas. JAMA Oncol. 2022;8:1263\u201370. https:\/\/doi.org\/10.1001\/jamaoncol.2022.2319.","journal-title":"JAMA Oncol"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19762-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-19762-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19762-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T13:38:09Z","timestamp":1783345089000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-19762-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["19762"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-19762-3","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"16 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CY received honoraria from AstraZeneca, Merck Sharp & Dohme, Servier, Eisai, Roche, Bristol Myers Squibb, Ipsen, Novartis, Boryung, Qurient, HLB, ABL Bio, Abbisko, CKD pharm, and Elevar Therapeutics and research grants from AstraZeneca, Ipsen, Servier, Boryung, Lunit Inc., and Boehringer Ingelheim. The remaining authors have no conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}},{"value":"This study (NCT04986930) was approved by the Institutional Review Board of Asan Medical Center, Seoul, Korea. Written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}